Considering the high fatality rate of this condition, if left untreated, as well as the wide availability of effective anti-malarial drugs, it seems appropriate to treat HMS even in case the classical triad of splenomegaly, raised IgM and anti-malarial antibodies is only partially satisfied. This evidence concerns the gene CD40LG and Haim-Munk syndrome.